# Index

*N*-acetyl-aspartate (NAA) 258  
*N*-acetylcysteine (NAC) 115  
active controlled trials, advantages and disadvantages 196  
affective spectrum disorders 146  
age of onset 140, 168  
aggressive obsessions, percentage in adults 4  
alcohol dependence  
  comorbidity with OCD 201  
alpha-methyl-para-tyrosine (AMPT) 229  
amisulpride 230  
γ-aminobutyric acid pathway 47  
D-amphetamine 32, 113, 229  
amygdala 252–3  
Anancastic Personality Disorder 152  
anorexia nervosa 135–6  
anterior lateral orbital frontal cortex (ALOFC) 257  
anterior limb of internal capsule (ALIC) as DBS target 86–90, 116  
mood changes 93  
antipsychotic agents  
  atypical (AAPs) 110–12  
  induced OCD symptoms 112  
  augmentation of SSRIs 44–5  
  AAP-induced OCD symptoms 112  
  effectiveness and long-term safety 109–12  
  typical 110  
antipsychotic augmentation of SSRIs 44–5  
antistreptolysin O antibody (ASO) 247–8  
anxiety and anxiety disorders 146  
evaluation in OCD 204–5  
Anxiety Disorders Interview Schedule for Children (ADIS-C) 171  
Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV) 8  
apomorphine 229  
aripiprazole  
  augmentation of SSRIs 111–12  
Asperger syndrome 173  
assay sensitivity 195, 196  
amusement 3–6, 22–23  
clinical assessment 9–10  
  Children’s Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) 171, 174  
  Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS) 11–12  
  Leyton Obsessional Inventory (LOI) 12–13, 65  
  Leyton Obsessional Inventory (LOI) – Child Version 13  
  Maudsley Obsessional-Compulsive Inventory (MOCI) 13, 317  
  Obsessive Compulsive Inventory – Child Version (OCI-CV) 171  
  Obsessive Compulsive Inventory – Revised (OCI-R) 14, 65  
  Obsessive Compulsive Inventory (OCI) 14  
  Padua Inventory – Revised (PI-R) 14  
  Padua Inventory – Washington State University Revision (PI-WSUR) 13–14  
  Padua Inventory (PI) 13–14  
  Yale–Brown Obsessive-Compulsive Scale (Y-BOCS) 10–11, 31, 64–5, 100, 203  
cognitive behavioural therapy (CBT) 64  
  self-report measures 65  
  components 5  
detecting OCD 6–7  
  screening in clinical interview 7–8  
  structured interviews 8–9  
differential diagnosis, comorbidities and related disorders 18–19  
  body dysmorphic disorder (BDD) 21–2  
  brain disorders 19–20  
  depression 20  
  hoarding 22  

---

INDEX

assessment (Continued)
  hypochondriasis 20–1
  obsessive-compulsive personality disorder (OCPD) 21
  other disorders 22
  phobias 21
  schizophrenia 20
  Tourette disorder 21
  insight 14–15
  rating 15–17
  suicide risk 17–18

attention-deficit hyperactivity disorder (ADHD) 162–4

attitudes towards OCD symptoms 6
atypical antipsychotics (AAPs) 110–12
induced OCD symptoms 112
autism 136, 137
OCSD category 140

Autism Spectrum Screening Questionnaire (ASSQ) 202

basal ganglia 246–8
behavioural addictions 139
binge eating disorder 135–6
body dysmorphic disorder (BDD) 19, 21–2, 135–6
endophenotyping and comorbidity 141
OCSD category 140

brain disorders, differential diagnosis of 19–20
brain endophenotyping 142–3
brain imaging 244, 266–7
  functional neuroimaging for OCD 255–7

neurochemistry
  N-acetyl-aspartate (NAA) 258
  choline (Cho) 259–61
  creatine/phosphocreatine (Cr) 262
  glutamate 262–6
  serotonin 258

neuroimaging modalities
  functional neurochemical assessment 245–6
  structural assessment 244–5
structural assessment of OCD
  basal ganglia 246–8
  medial temporal-limbic cortex 252–3
  pituitary 253
  prefrontal cortex 248–52
  supramarginal gyrus 253–4
  total volume/ventricles 246
  white matter 254
bromocriptine 229
Brown Assessment of Beliefs Scale (BABS) 16
buspirone 106
caffeine 113
anatomical and neurofunctional targets 118
Cambridge Neurophysiological Test Automated Battery (CANTAB) 308
candidate gene studies 285–9
caudate nucleus 114
endophenotyping 142
checking compulsions, percentage in adults 4
children see paediatric OCD
Children’s Florida Obsessive Compulsive Inventory (FOCI) 65, 171
Children’s Obsessive Compulsive Inventory (CHOCI) 171
Children’s Yale–Brown Obsessive-Compulsive Scale (CY–BOCS) 171, 174
chlorpromazine
  induced OCD symptoms 112
cholera toxin (CT) 231
choline (Cho) 259–61
cingulate grey matter increase in OCD 248
citalopram
  infusion therapy 104
  meta-analyses 38–40
  paediatric OCD 38
  placebo-controlled trials 34–5
  rate of clinical response 206
  refractory OCD 44
  switching 103
Clinical Global Impression (CGI) scale 31, 100–1
  Severity and Improvement Scales 203
clinical treatment trial methodologies 193–4, 211–12
  anxiety and depression evaluation 204–5
  comorbidity problems 201–2
  diagnosis 199–200
  Health Related Quality of Life (HRQoL) 211
  integrated pharmacological and psychological treatments 210–11
  OCD dimensions and subtypes 200–1
  placebo, rationale of 196–9
  psychological treatment trials 209–10
  randomised controlled trials (RCTs) 194–6
  rating scales 203–4
  recruitment criteria 199
  relapse prevention 207–8
  response and remission measurements 205–7
  treatment resistance 208–9
clozapine (CMI)
dose 41
duration 42
  effect on HVA levels 228
  infusion therapy 104
lamotrigine augmentation 266
meta-analyses 38–40
<table>
<thead>
<tr>
<th>INDEX</th>
<th>333</th>
</tr>
</thead>
<tbody>
<tr>
<td>paediatric OCD 36, 175</td>
<td>deep brain stimulation (DBS) 47–8, 86</td>
</tr>
<tr>
<td>placebo-controlled trials 32</td>
<td>conclusions 94</td>
</tr>
<tr>
<td>rate of clinical response 206</td>
<td>efficacy in OCD 86, 88–9</td>
</tr>
<tr>
<td>selectivity for serotonin 225</td>
<td>anterior limb of internal capsule (ALIC) 86–90, 116</td>
</tr>
<tr>
<td>tolerability 40–1</td>
<td>conclusions 91–2</td>
</tr>
<tr>
<td>clonazepam 45, 107</td>
<td>nucleus accumbens (NAcc) 90–1, 116–17</td>
</tr>
<tr>
<td>clorgyline 32</td>
<td>subthalamic nucleus (STN) 91, 117</td>
</tr>
<tr>
<td>clozapine 45</td>
<td>thalamic peduncle 91</td>
</tr>
<tr>
<td>augmentation of SSRIs 112</td>
<td>ventral capsule/ventral striatum (VC/VS) 90</td>
</tr>
<tr>
<td>induced OCD symptoms 112</td>
<td>follow-up treatment 94</td>
</tr>
<tr>
<td>cocaine 229</td>
<td>mechanism of action 92</td>
</tr>
<tr>
<td>cognitive Assessment Instrument of Obsessions and Compulsions (CAIOC) 203</td>
<td>refractory OCD 116–17</td>
</tr>
<tr>
<td>cognitive behavioural therapy (CBT) 69–70</td>
<td>side effects 92–4</td>
</tr>
<tr>
<td>augmentation of pharmocotherapies 105–6</td>
<td>deep TMS 85</td>
</tr>
<tr>
<td>before-and-after neuroimaging 256</td>
<td>delusional disorder 14</td>
</tr>
<tr>
<td>clinical trials 209–10</td>
<td>delusions 14–15</td>
</tr>
<tr>
<td>dissemination 67–8</td>
<td>depersonalization disorder 135–6</td>
</tr>
<tr>
<td>future directions 69</td>
<td>depression 20</td>
</tr>
<tr>
<td>paediatric OCD 173, 175</td>
<td>evaluation in OCD 204–5</td>
</tr>
<tr>
<td>protocols</td>
<td>improvement following DBS 93</td>
</tr>
<tr>
<td>adult protocol 65–7</td>
<td>desipramine 32</td>
</tr>
<tr>
<td>assessment 64</td>
<td>dexamfetamine 113</td>
</tr>
<tr>
<td>paediatric protocol 67</td>
<td>anatomical and neurofunctional targets 118</td>
</tr>
<tr>
<td>theoretical models 58–9</td>
<td>diagnosis, differential</td>
</tr>
<tr>
<td>treatment</td>
<td>body dysmorphic disorder (BDD) 21–2</td>
</tr>
<tr>
<td>cognitive therapies 63</td>
<td>brain disorders 19–20</td>
</tr>
<tr>
<td>exposure plus response prevention (ERP) 60–63</td>
<td>depression 20</td>
</tr>
<tr>
<td>exposure plus response prevention (ERP) plus medication 63–4</td>
<td>hoarding 22</td>
</tr>
<tr>
<td>Columbia Suicide Severity Rating Scale (C-SSRS) 202</td>
<td>hypochondriasis 20–1</td>
</tr>
<tr>
<td>comorbidities to paediatric OCD 169–170</td>
<td>obsessive-compulsive personality disorder (OCPD) 21</td>
</tr>
<tr>
<td>Composite International Diagnostic Interview (CIDI) 9</td>
<td>other disorders 22</td>
</tr>
<tr>
<td>compulsions</td>
<td>paediatric OCD</td>
</tr>
<tr>
<td>definition 4</td>
<td>normal development 172</td>
</tr>
<tr>
<td>percentages in adults 4</td>
<td>other psychiatric disorders 172–3</td>
</tr>
<tr>
<td>screening for 8</td>
<td>phobias 21</td>
</tr>
<tr>
<td>compulsive hoarding 151–4</td>
<td>schizophrenia 20</td>
</tr>
<tr>
<td>compulsivity 137–8</td>
<td>Tourette disorder 21</td>
</tr>
<tr>
<td>computerized tomography (CT) 244–5</td>
<td>diffusion tensor imaging (DTI) 245</td>
</tr>
<tr>
<td>contamination obsessions, percentage in adults 4</td>
<td>Dimensional Yale–Brown Obsessive–Compulsive Scale (DY–BOCS) 11–12</td>
</tr>
<tr>
<td>cortico-striato-thalamo-cortical (CSTC) network 47, 92</td>
<td>disease, hierarchical model 305, 306</td>
</tr>
<tr>
<td>counting compulsions, percentage in adults 4</td>
<td>dissociative disorders 146</td>
</tr>
<tr>
<td>creatine (Cr) 262</td>
<td>dizygotic twins (DZ) 277, 301–2, 317</td>
</tr>
<tr>
<td>Cushing's syndrome 261</td>
<td>dopamine 227</td>
</tr>
<tr>
<td>d-cycloserine (DCS) 47</td>
<td>animal models 231–2</td>
</tr>
<tr>
<td>CBT augmentation 105–6</td>
<td>importance of location 234–5</td>
</tr>
<tr>
<td>cytochrome 450 (CYP450) isoenzymes 46</td>
<td>pharmacological challenge tests 228–9</td>
</tr>
<tr>
<td></td>
<td>pharmacotherapy</td>
</tr>
<tr>
<td></td>
<td>antagonists 229–30</td>
</tr>
<tr>
<td></td>
<td>antagonists in addition to SSRIs 230–1</td>
</tr>
<tr>
<td></td>
<td>role in OCD 234</td>
</tr>
</tbody>
</table>
dopaminergic agents, rationale for use 108–9
dorsolateral prefrontal cortex (DLPFC) as rTMS target 82–3
duloxetine, switching 103
Dutch Dimensional Obsessive Compulsive Scale (D-DOCS) 203
eating disorders
comorbidity with OCD 201
endophenotyping and comorbidity 141
electroconvulsive therapy (ECT) 75–6
refractory OCD 115
electroencephalography (EEG) 246
endophenotypes 300–1, 317–19
application to OCD 305–7
definition 302–5
domains for modelling OCD
cognition 307–8
neuroimaging 308–11
heritability of OCD 301–2
searching for OCD endophenotypes

cognition 311–13
neuroimaging 313–16
other potential endophenotypes 316–17
epigeneic processes 303
escitalopram
dose 41
placebo-controlled trials 34–5
rate of clinical response 206
refractory OCD 44
ethics committee 194
exposure plus response prevention (ERP)
adult protocol 65–7
augmentation of pharmacotherapies 105–6
clinical trials 209
duration of exposure 62
exposure session frequency 61–2
exposure versus response prevention 60–1
family involvement 62–3
gradual versus abrupt exposures 62
imaginal exposure 61
implementation 61
paediatric protocol 67
procedures 60
families of sufferers
early onset increases familial risk 161–2
exposure plus response prevention (ERP) 62–3
genetics of OCD 279–80
associated conditions 283–4
family history studies 280
interview studies 280–4
role in OCD 166
treatment resistance 117
fenfuramine 224
first-degree relative risk 301
Fixity of Beliefs Scale 16–17
Florida Obsessive Compulsive Inventory (FOCI), children’s 171
[18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) 152–3
fluoxetine
duration 42–3
meta-analyses 38–40
paediatric OCD 36–7
placebo-controlled trials 33
rate of clinical response 206
refractory OCD 44
switching 103
tolerability 40–1
fluvoxamine
dose 41
meta-analyses 38–40
paediatric OCD 36
placebo-controlled trials 32–3
rate of clinical response 206
refractory OCD 44
switching 103–4
tolerability 41
Foa and Kozak’s Emotional Processing Theory 59
fractional anisotropy (FA) 315
full response to treatment 101
functional magnetic resonance imaging (fMRI) 246, 311
future directions for OCD research 328–9
gambling, pathological 19, 136, 202
gamma knife 86
gender and OCD 168
genetic factors for OCD
early onset increases familial risk 161–2
tic- and ADHD-related OCD in youth 162–4
genetics of OCD 277
candidate gene studies 285–9
family studies 279–80

associated conditions 283–4
family history 280
family interviews 280–4
future directions 291–2
genetic linkage studies 290–1
segregation analyses 284–5
twin studies 277–9
genome-wide association studies (GWAS) 291
globus pallidus volume reduction 247
glutamate 232, 262–6
animal models 233
concentrations in humans 232
glutaminergic influence 232
INDEX

glutamate pathway 47
 glutamatergic agents
 augmentation 114–15
 rationale for use 113–14
 good clinical practice (GCP) 194
 Graves disease 261
 group A beta-haemolytic streptococcus (GABHS) 172

haloperidol 44, 109
 augmentation of SSRIs 110
 Hamilton Anxiety Rating Scale 204
 Hamilton Depression Rating Scale (HDRS) 204
 Health Related Quality of Life (HRQoL) 101, 202, 211
 heritability of OCD 301–2
 hierarchical model of disease 305, 306
 higher-order repetitive behaviours 138–9
 hippocampus 252
 hoarding 22
 compulsive 151–4
 percentage in adults 4
 obsessions
 percentage in adults 4
 homovanillic acid (HVA) 227
 5-HT transporter (5-HTT), efficacy of antidepressants in OCD 225
 Huntingdon’s chorea 19
 OCSD category 140
 5-hydroxyindolacetic acid (5-HIAA) 221, 222
 Tourette’s syndrome 222
 5-hydroxytryptamine (5-HT) see serotonin
 hypochondriasis 19, 20–1, 135–6
 hypothalamic-pituitary-adrenal (HPA) axis 253

imaginal exposure 60, 61
 imipramine 32
 impulse control disorders (ICDs) 135–6
 endophenotyping and comorbidity 141
 OCSD category 140
 not otherwise specified 139
 impulsivity 137–8
 inositol 45
 integrated pharmacological and psychological treatments 210–11
 interviews
 clinical screening 7–8
 structured 8–9
 intracranial brain volume 246
 Intra-dimensional/Extra-dimensional (IDED) set-shift task 308
 intravenous immunoglobulin (IVIG) 177
 Iowa Gambling and Delayed Alternation tests 312
 ipsapirone 224

lamotrigine 266
 learning disabilities (LDs) 169
 lesioning 85–6
 Leyton Obsessional Inventory (LOI) 12–13, 65
 Child Version 13
 family interview studies 280
 paediatric OCD 171
 limbic-hypothalamic-pituitary-adrenal (LHPA) axis 253
 lithium 107
 log odds (LOD) scores 290
 lower-order repetitive behaviours 138, 139
 Lynfield Obsessional Compulsive Questionnaire 13, 65
 magnetic resonance imaging (MRI) 244–5
 magnetic resonance spectroscopy (MRS) 246
 magnetoencephalography (MEG) 246
 Major Depressive Disorder (MDD) 260
 Maudsley Obsessional-Compulsive Inventory (MOCI) 13, 317
 medial temporal-limbic cortex 252–3
 memantine 114, 266
 metachlorophenylpiperazine (mCPP) 224
 N-methyl-D-aspartic acid (NDMA) 47
 CBT augmentation 105
 methylphenidate 113, 229
 Mini International Neuropsychiatric Interview (MINI) 7, 9
 mirtazapine, switching 103
 monoamine oxidase (MAO) 266
 monozygotic twins (MZ) 277, 301–2, 317
 Montgomery and Asberg Depression Rating Scale (MADRS) 202, 204
 mood changes following DBS of ALIC and NAcc 93
 Mowrer’s two-stage theory 58
 Multidimensional Anxiety Scale for Children (MASC) 172
 myelin 254
 naltrexone 115
 National Institute for Mental Health Global Obsessive-Compulsive Scale 203
 neuroimaging see brain imaging
 neurological disorders with repetitive behaviours 135, 137
 Neurological Soft Sign Examination 201
 neurotransmitters 220–1
 dopamine 227
 animal models 231–2
 importance of location 234–5
 pharmacological challenge tests 228–9
neurotransmitters (Continued)
pharmacotherapy 229–31
role in OCD 234
glutamate 232
animal models 233
concentrations in humans 232
glutamatergic influence 232
serotonin 221–2
animal models 226–7
importance of location 234–5
pharmacological challenge tests 224–5
pharmacotherapy 225–6
role in OCD 222–4, 233
non-genetic factors for OCD
adverse perinatal factors 164–5
family, role of 166
pediatric autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS) 165–6
trauma and stress 166–7
non-inferiority trials 196
non-response to treatment 101
nortriptyline 32
nucleus accumbens (NAcc) as DBS target 90–1, 116–17
mood changes 93
obsessions
definition 3
percentages in adults 4
screening for 8
Obsessive Beliefs Questionnaire (OBQ) 316–17
Obsessive Compulsive Inventory (OCI) 14, 203–4
Child Version (OCI-CV) 171
Revised (OCI–R) 14
Revised (OCI–WSUR) 14
 Obsessive-compulsive disorder (OCD) endophenotyping and comorbidity 141
OCSD category 140
subtypes see subtypes of OCD
summary and conclusions 327–9
obsessive-compulsive personality disorder (OCPD) 21, 139, 316
obsessive-compulsive spectrum disorders (OCSDs) 135
age of onset 140
cluster approach 135–7
compulsivity and impulsivity 137–8
diagnostic criteria, suggested 144
endophenotyping and comorbidity 141
nosology 144–8
placement using cross-cutting domains 139–44
repetitive behaviour domain 138–9
olanzapine 44, 109
augmentation of SSRIs 111
induced OCD symptoms 112
ondansetron 107–8
anatomical and neurofunctional targets 118
opioids 115
Oppositional Defiant Disorder (ODD) 175–6
orbitofrontal cortex (OFC)
as rTMS taget 83
endophenotyping 142
 glutamatergic transmission to caudate nucleus 114
serotonin release 225
orbito-fronto-striatal cortical loop hypothesis of OCD 309–10
ordering compulsions, percentage in adults 4
Overvalued Ideas Scale (OVIS) 16
P50 inhibition 304
Padua Inventory (PI) 13–14
Revised (PI–R) 14
Washington State University Revision (PI–WSUR) 13–14
Paediatric Anxiety Rating Scale (PARS) 171
paediatric OCD 160
aetiological considerations
 genetic factors 161–4
non-genetic factors 164–7
summary 167
clinical assessment 171–2
clinical features 167–8
comorbid conditions 169–170
gender and age of onset 168
neuropsychological endophenotypes 170
phenotypic dimensions 168
summary 170
course and prognosis 179
differential diagnosis
normal development 172
other psychiatric disorders 172–3
epidemiology 160–1
exposure plus response prevention (ERP) 67
future directions 179–80
Pediatric OCD Treatment Study (POTS) 63–4
pharmacotherapy 36
citalopram 38
clozapine 36
clozapine 36
fluoxetine 36–7
fluvoxamine 36
paroxetine 37
sertraline 37
treatment 173–4
augmentation in treatment resistance 177–8
moderating effect of comorbid conditions 175–6
multimodal treatment 176
pharmacotherapy 174–5
safety and tolerability 178
summary 178–9
paired relative-proband design 312
panic disorder, comorbidity with OCD 201
parietal lobe 253–4
Parkinson’s disease 19–20, 108
OCSD category 140
paroxetine 46–7
cerebral metabolic changes 257
duration 43
lowest efficacious dose 195
meta-analyses 38–40
paediatric OCD 37, 175–6
placebo-controlled trials 34
rate of clinical response 206
refractory OCD 44
switching 103
partial response to treatment 101
pediatric autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS) 5, 165–6
diagnostic criteria 165
OCSD category 140
Pediatric OCD Treatment Study (POTS) 63–4, 173, 175
perinatal factors in OCD 164–5
pervasive developmental disorder (PDD) 172, 173
pharmacotherapy 31–2
see also under drug names
before-and-after neuroimaging 256
duration 42–3
future options 47–8
improving early response 35
meta-analyses 38–40
optimal dose 41–2
paediatric OCD 36, 174–5
citalopram 38
clo mipramine 36
fluoxetine 36–7
fluvoxamine 36
paroxetine 37
sertraline 37
placebo-controlled trials
citalopram/ecitalopram 34–5
clo mipramine 32
fluoxetine 33
fluvoxamine 32–3
paroxetine 34
sertraline 34
venlafaxine 35
refractory OCD 43
see also treatment resistance
adding psychotherapy 47
alternative administration of SSRIs 46
antipsychotic augmentation of SSRIs 44–5
combining SSRIs 46
increased SSRI dose 43–4
other drug augmentation of SSRIs 45–6
switching SSRIs 46–7, 103–4
tolerability of clomipramine and SSRIs 40–1
phenelzine 33
phobias 21
comorbidity with OCD 201
phosphocreatine 262
pimozide, augmentation of SSRIs 110
pindolol 35, 45, 107
effect on SSRIs 225
pituitary 253
placebo-controlled trials 196–9
recommended safeguards 199
positron emission tomography (PET) 245–6
post-traumatic stress disorder (PTSD) 146
prefrontal cortex 248–52
prevalence of OCD 3
proton magnetic resonance spectroscopy (1H MRS) 258
psychotherapy 48
adding to pharmacotherapy 47
psychotic disorder not otherwise specified 14
putamen volume reduction in TS 247
quetiapine 44–5, 109
augmentation of SSRIs 111
induced OCD symptoms 112
quinpirole (QNP) 231
randomised controlled trials (RCTs) 194–6
recovery 101
refractory OCD 101
see also treatment resistance
pharmacotherapy 43
adding psychotherapy 47
alternative administration of SSRIs 46
antipsychotic augmentation of SSRIs 44–5
combining SSRIs 46, 103–4
increased SSRI dose 43–4
other drug augmentation of SSRIs 45–6
switching SSRIs 46–7
region-of-interest approach 310
relapse following treatment 101
relapse prevention 207–8
religious obsessions, percentage in adults 4
remission 101, 207
repeating rituals compulsions, percentage in adults 4
repetitive behaviour 138–9
neurological disorders 135
neurological disorders 137
repetitive transcranial magnetic stimulation (rTMS) see transcranial magnetic stimulation (TMS)
response to treatment stages 101
riluzole 114–15, 265–6
risk averse/harm avoidant behaviours 137
risperidone 44, 109
  anatomical and neurofunctional targets 118
  augmentation of SSRIs 110–11
  induced OCD symptoms 112
Salkovski’s five dysfunctional assumptions 59
Schedule for Affective Disorders and Schizophrenia (SADS) 202
schizophrenia 20
Screen for Child Anxiety Related Emotional Disorders (SCARED) 171–2
screening for OCD 7–8
segregation analyses 284–5
seizure risk 40
selective serotonin reuptake inhibitors (SSRIs)
  see also under drug names
  anatomical and neurofunctional targets 118
  antipsychotic augmentation
    AAP-induced OCD symptoms 112
    effectiveness and long-term safety 109–12
  dexamfetamine and caffeine 113
  dopamine antagonists 230–1
  infusion therapy 104
  meta-analyses 38–40
  mortality rates 41
  optimal dose 41–2
  paediatric OCD 175
  safety and tolerability 178
  refractory OCD 43
  adding psychotherapy 47
  alternative administration 46
  antipsychotic augmentation 44–5
  combining SSRIs 46
  increased dose 43–4
  other drug augmentation 45–6
  switching SSRIs 46–7
  response time 35
  switching to clomipramine 103
  thalamic volume decrease 250–2
  tolerability 40–1
  serotonin (5-hydroxytryptamine; 5-HT) 221–2, 258
  animal models 226–7
  importance of location 234–5
  pharmacological challenge tests 224–5
  pharmacotherapy 225–6
    role in OCD 222–4, 233
  serotonin and noradrenaline reuptake inhibitors (SNRIs) 35
  serotonergic agents 106–8
  sertraline
    dose 42
    meta-analyses 38–40
    paediatric OCD 37, 175
    placebo-controlled trials 34
    rate of clinical response 206
    refractory OCD 44
    switching 103
    tolerability 40–1
  sexual compulsions 136
  percentage in adults 4
  Sheehan Disability Scale (SDS) 203
  Short-Form-36 203
  single nucleotide polymorphisms (SNPs) 291, 302
  single-photon emission computerized tomography (SPECT) 245–6
  skin-picking disorder 18
  SLC6A4 HTTLPR marker 161–2
  social anxiety disorder, comorbidity with OCD 201
  soft signs for OCD 201
  somatic obsessions, percentage in adults 4
  stages of treatment response 101
  State Trait Anxiety Inventory (STAI) 204–5
  Stevens–Johnson syndrome 266
  stop-signal reaction time (SSRT) 308, 313
  stop-signal test (SST) 307–8
  stress and paediatric OCD 166–7
  stress management training (SMT) 105
  striatal volume reduction 247
  structural equation modelling (SEM) 302
  Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID-I) 9
  Structured Clinician-Administered Interview for the Diagnosis of Obsessive-Compulsive Spectrum Disorders (SCID-OCSD) 202
  substance use disorders (SUDs)
    endophenotyping and comorbidity 141
    OCSD category 140
  subthalamic nucleus (STN) as DBS target 91, 117
  subtypes of OCD 148
    associated symptom domains 150–1
    compulsive hoarding 151–4
    dimensional approach 148–50
  suicide
    Columbia Suicide Severity Rating Scale (C-SSRS) 202
    risk assessment 17–18
INDEX

sumatripan 224
supplementary motor area (SMA) as rTMS target 83–4
supramarginal gyrus 253–4
Sydenham chorea 108, 136, 137
symmetry obsessions, percentage in adults 4
thalamic peduncle as DBS target 91
thalamus
endophenotyping 142
volume decrease with SSRIs 250–2
theta burst stimulation (TBS) 85
tics 201
topiramate 115
total brain volume 246
Tourette syndrome/disorder (TS) 5, 21, 108, 136, 137
association with OCD 162
comorbidity with OCD 169, 201
endophenotyping and comorbidity 141
5-HIAA levels 222
OCSD category 140
putamen volume reduction 247
tramadol 115
transcranial magnetic stimulation (TMS)/repetitive transcranial magnetic stimulation (rTMS) 48, 76–7
deep TMS 85
efficacy in OCD 77–82
dorsolateral prefrontal cortex (DLPFC) 82–3
orbitofrontal cortex (OFC) 83
supplementary motor area (SMA) 83–4
future directions 85
mechanism 77
refractory OCD 116
side effects and safety 84–5
trauma and paediatric OCD 166–7
trazodone 107
treatment resistance 99
clinical trials 208–9
definitions 100–3
family intervention 117
future directions 117–18
paediatric OCD 177–8
pharmacological strategies
CBT augmentation 105–6
dopaminergic agents 108–13
glutamergic agents 113–15
infusion therapy 104–5
opioids 115
serotoninergic agents 106–8
switching SSRIs 103–4
physical strategies
ECT 115
trichotillomania (TTM) 18, 136
autistic children 139
endophenotyping and comorbidity 141
OCSD category 140
tricyclic antidepressants (TCAs), mortality rates 41
twin studies 277–9, 301–2, 317
typical antipsychotics 110
venlafaxine 46–7
placebo-controlled trials 35
switching 103
ventral capsule/ventral striatum (VC/VS) as DBS target 90
ventricular brain ratios (VBR) 246
voxel-based morphometry (VBM) 245, 311
washing/cleaning compulsions, percentage in adults 4
white matter volume 254
Wisconsin Card Sorting Test 308
Yale Global Tic Severity Scale (YGTSS) 201
Yale–Brown Obsessive-Compulsive Scale (Y–BOCS) 10–11, 31, 64–5, 100, 101–2
Yale–Brown Obsessive-Compulsive Scale II (Y–BOCS-II) 101
Dimensional (DY–BOCS) 11–12
ziprasidone, augmentation of SSRIs 112
Zohar–Fineberg Obsessive Compulsive Screen (ZF-OCS) 7
zolmitriptan 224